NEW ONSET OF TYPE 1 DIABETES MYCOPHENOLATE MOFETIL-DACLIZUMAB

新发 1 型糖尿病 麦酚酸吗替尔-达利珠单抗

• 批准号: 7982161
• 负责人: FRANCINE R. KAUFMAN
• 金额: $ 0.12万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982161
• 关键词: American; Autoimmune Diseases; Autoimmune Process; Beta Cell; Biological Preservation; Caring; Chronic; Clinical Research; Clinical trial protocol document; Complications of Diabetes Mellitus; Computer Retrieval of Information on Scientific Projects Database; Daclizumab; Diabetes Mellitus; Disease; Foundations; Funding; Grant; Human; Hypoglycemia; Immune; Immunosuppression; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; International; Intervention; Metabolic Control; National Center for Research Resources; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; Pancreas; Production; Research; Research Personnel; Resources; Source; Time; United States National Institutes of Health; Work; cost; diabetes control; diabetic; immunoregulation; improved; insulin dependent diabetes mellitus onset; islet; mycophenolate mofetil; outcome forecast; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. NEW ONSET OF TYPE 1 DIABETES MYCOPHENOLATE MOFETIL ¿?? DACLIZUMAB CLINICAL TRIAL (Protocol TN-02) Preservation of Pancreatic Production of Insulin through Immunosuppression - 1 Study EDITION: May 30, 2007 IND 11528 Version 2.0 Sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases; NIDDK;, the National Institute of Allergy and Infectious Diseases; NIAID;, the National Institute of Child Health and Human Development , the National Center for Research Resources, the Juvenile Diabetes Research Foundation International;, and the American Diabetes Association;. The great body of evidence developed over the last 10 ¿?? 20 years suggests that type 1 diabetes in humans is a chronic, slowly progressive autoimmune disease. The objective of this study is to identify immune intervention strategies that will prevent the progression of beta cell destruction from the time of onset of type 1 diabetes. The persistence of at least some beta cells should improve long-term diabetes care and prevent not only complications of the disease itself but also hypoglycemia, which is a consequence of its management. The aim is to arrest beta cell destruction in newly diabetic subjects because immune modulation may not work well alone once the autoimmune process has progressed to complete or near complete destruction of beta cells. The complications of long-term diabetes are well known, and the costs of caring for diabetes and its complications are currently greater than $100 billion a year. The Diabetes Control and Complications Trial and other studies have demonstrated that improved metabolic control can reduce the long-term complications of diabetes [6]. Thus, an intervention, which could restore normal islet function and maintain production of insulin would significantly improve the prognosis for metabolic control of diabetes and thus reduce long-term complications.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 新的1型糖尿病发病的霉酚酸酯莫非汀？？达克珠单抗临床试验 （方案TN-02） 通过免疫抑制保护胰腺产生胰岛素- 1研究版本：2007年5月30日 IND 11528 2.0版 由国家糖尿病、消化和肾脏疾病研究所、国家过敏和传染病研究所、国家儿童健康和人类发展研究所、国家研究资源中心、国际青少年糖尿病研究基金会和美国糖尿病协会赞助。 大量的证据在过去的10年里发展起来？？20年的研究表明，人类1型糖尿病是一种慢性、缓慢进行性的自身免疫性疾病。本研究的目的是确定免疫干预策略，以防止从1型糖尿病发作时β细胞破坏的进展。至少一些β细胞的持续存在应该改善长期糖尿病护理，不仅可以预防疾病本身的并发症，还可以预防低血糖，这是其管理的结果。目的是阻止新糖尿病受试者中的β细胞破坏，因为一旦自身免疫过程已经进展到β细胞的完全或接近完全破坏，免疫调节可能无法单独良好地起作用。 长期糖尿病的并发症是众所周知的，目前每年治疗糖尿病及其并发症的费用超过1000亿美元。糖尿病控制和并发症试验和其他研究表明，改善代谢控制可以减少糖尿病的长期并发症[6]。因此，可以恢复正常胰岛功能并维持胰岛素产生的干预措施将显著改善糖尿病代谢控制的预后，从而减少长期并发症。